Harold Jacob - Nov 15, 2023 Form 4 Insider Report for NanoVibronix, Inc. (NAOV)

Role
Chief Medical Officer, Director
Signature
/s/ Harold Jacob, MD
Stock symbol
NAOV
Transactions as of
Nov 15, 2023
Transactions value $
$0
Form type
4
Date filed
12/4/2023, 08:45 PM
Previous filing
Jan 3, 2022
Next filing
Feb 26, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAOV Option to Purchase Common Stock Award $0 +3.33K $0.00 3.33K Nov 15, 2023 Common Stock 3.33K $1.24 Direct F1
transaction NAOV Option to Purchase Common Stock Disposed to Issuer $0 -2.5K -100% $0.00* 0 Nov 29, 2023 Common Stock 2.5K $20.20 Direct F2, F4
transaction NAOV Option to Purchase Common Stock Disposed to Issuer $0 -2.5K -100% $0.00* 0 Nov 29, 2023 Common Stock 2.5K $8.94 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the option vested on November 15, 2023, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan.
F2 25% of the option vested on December 29, 2021 (the "2021 Date of Grant"), with an additional 25% to vest on the three-month anniversary of the 2021 Date of Grant, a further 25% to vest on the six-month anniversary of the 2021 Date of Grant, and the final 25% to vest on the nine-month anniversary of the 2021 Date of Grant, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan.
F3 25% of the option vested on September 13, 2022 (the "2022 Date of Grant"), with an additional 25% to vest on the three-month anniversary of the 2022 Date of Grant, a further 25% to vest on the six-month anniversary of the 2022 Date of Grant, and the final 25% to vest on the nine-month anniversary of the 2022 Date of Grant, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan.
F4 The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations.